AOD-9604 vs Tesamorelin.

Two GH-pathway fat loss compounds compared: the lipolytic fragment versus the GHRH analog, with different mechanisms, evidence levels, and metabolic effects.

Fat LossGH PathwayComparisonLipolysis
AOD-9604 and tesamorelin both leverage the growth hormone pathway for fat loss, but they do so through fundamentally different mechanisms. AOD-9604 is a modified fragment of GH that retains lipolytic activity without growth effects. Tesamorelin stimulates the pituitary to release endogenous GH, producing the full spectrum of GH effects including visceral fat reduction. This comparison helps clarify which approach better aligns with specific fat loss research objectives and safety considerations.
◆ ◆ ◆

Head-to-Head Comparison.

Full NameAOD-9604 (Anti-Obesity Drug 9604)Tesamorelin Acetate (Egrifta SV)
OriginGH fragment (amino acids 176-191), modifiedSynthetic GHRH analog with hexenoic acid
FDA StatusNot approved (Category 1)FDA Approved (2010)
Power Rating
3/5
5/5
MechanismDirect lipolysis via GH-receptor-independent pathwayGHRH-R stimulation for endogenous GH release
Fat Loss MechanismStimulates lipolysis + inhibits lipogenesis in adiposeGH-mediated lipolysis, especially visceral fat
Growth EffectsNone (isolated lipolytic fragment)Full GH spectrum (lean mass, recovery, IGF-1)
Diabetogenic RiskNone (does not affect glucose/insulin)Low (modest glucose effects)
IGF-1 ElevationNoYes (GH drives hepatic IGF-1 production)
Clinical TrialsPhase IIb (Metabolic Pharmaceuticals, 2007)Phase III (approved)
Trial OutcomeFailed primary endpoint (modest 1.6kg loss)Succeeded: 15-18% trunk fat reduction
Regulatory StatusGRAS status in Australia (food use)FDA-approved prescription drug
AdministrationSubcutaneous injectionSubcutaneous injection
CostLower (research compound)Higher (pharmaceutical pricing)
◆ ◆ ◆

How They Target Fat Differently.

AOD-9604 takes a surgical approach: it isolates the lipolytic activity of the GH molecule without any of the growth-promoting, insulin-antagonist, or IGF-1-elevating effects. It works through a mechanism independent of the GH receptor, directly stimulating lipolysis in adipocytes and inhibiting lipogenesis. This makes it metabolically clean but limited in scope. Tesamorelin takes the opposite approach: by stimulating endogenous GH release, it produces the full spectrum of GH effects. Fat loss occurs through GH-mediated lipolysis with a preference for visceral adipose depots. But you also get the metabolic effects of elevated GH and IGF-1: lean mass support, recovery enhancement, and connective tissue benefits. The tradeoff is that full-spectrum GH effects include potential glucose metabolism impacts and IGF-1 elevation that requires monitoring.

Clinical Evidence Gap.

The evidence gap between these two compounds is significant. Tesamorelin has passed Phase III trials with statistically significant visceral fat reduction (15-18% trunk fat over 26 weeks) and FDA approval. AOD-9604 underwent Phase IIb clinical trials but failed to meet its primary weight loss endpoint, showing only modest 1.6kg total weight loss over 12 weeks. This is a critical distinction: AOD-9604 is popular in the research peptide community despite failing a clinical trial, while tesamorelin succeeded and earned regulatory approval. AOD-9604 proponents argue the trial design (oral formulation, short duration, general obesity population) did not adequately test the compound. Its GRAS status in Australia for food applications suggests safety, but does not establish weight loss efficacy.

Safety Comparison.

AOD-9604 has a clean metabolic safety profile: no effects on glucose, insulin, IGF-1, or growth parameters. This makes it one of the safest compounds in the fat loss peptide space from a metabolic standpoint. Tesamorelin has more documented side effects (injection site reactions, arthralgia, peripheral edema) and elevates IGF-1, which requires monitoring. It is contraindicated in active malignancy and pregnancy. However, tesamorelin safety is well-characterized through clinical trials and years of pharmaceutical use, while AOD-9604 safety data is less comprehensive despite its favorable theoretical profile.

Choosing Between Them.

The choice depends on what you need beyond fat loss. If the goal is isolated lipolysis without affecting any other metabolic parameter, AOD-9604 provides a targeted approach, albeit with a weaker evidence base. If the goal includes visceral fat specifically, along with the broader metabolic benefits of GH optimization (lean mass support, recovery, connective tissue), tesamorelin offers the full package with clinical validation. Many researchers use AOD-9604 in combination protocols (like the Recomp Stack with CJC-1295/Ipa + MOTS-C) where it provides a complementary lipolytic signal without the complexity of additional GH-axis stimulation.

◆ The Verdict

For evidence-backed visceral fat reduction: Tesamorelin is the clear winner. FDA approval, Phase III data, and 15-18% trunk fat reduction make it the gold standard for GH-pathway fat loss.

For clean, isolated lipolysis in stacking protocols: AOD-9604 offers targeted fat-mobilizing activity without affecting glucose, insulin, or IGF-1. Its value is greatest when used as a component in multi-compound protocols where other compounds handle GH optimization.

Bottom line: Tesamorelin is the stronger standalone compound with superior evidence. AOD-9604 is a useful component piece for protocols where isolated lipolysis is needed without additional metabolic complexity.
◆ ◆ ◆

Source These Compounds.

Verified research peptide suppliers

BioPure Peptides

Premium research peptides with third-party COAs. Use code POWER at checkout.

Code: POWER
Shop Now →

Apollo Peptide Sciences

Research-grade peptides with Refersion-tracked affiliate program.

Shop Now →

Midwest Peptide

US-based peptide supplier. 10% off with code POWER, 30-day cookie.

Code: POWER
Shop Now →

Amino Club

20% off your first order with code POWER. Age-gated storefront.

Code: POWER
Shop Now →

Offline Peptides

75+ peptides, HPLC-verified, third-party COAs. Free shipping $250+.

Shop Now →
◆ ◆ ◆

Frequently Asked Questions.

Research Disclaimer: Content on PowerPeptides.co is for informational and research purposes only. It is not medical advice. Peptides discussed are research compounds unless explicitly noted as FDA-approved. Always consult a licensed healthcare provider before beginning any peptide protocol. Full Disclaimer | Affiliate Disclosure